Protein folding is a fundamental function in the mundane operations of a cell’s daily life. Yet, when this task goes wrong, it becomes readily apparent how vital of a role 3D structure plays for the vast majority of protein molecules.
In the past, scientists concluded that the aberrantly assembled proteins were the result of certain metabolic disorders, but new evidence from investigators at the Medical University of South Carolina (MUSC) suggests that the cell’s response to unfolded or misfolded proteins could be a cause, rather than a consequence, of metabolic disorders.
In the field of metabolic diseases, we are proud of our portfolio of stable and effective animal models, especially those for Non-alcoholic Fatty Liver Disease (NAFLD). Though popular recently, they still lack effective drug treatment.
Findings from the new study were published recently in Nature Structural & Molecular Biology in an article entitled “CNPY2 Is a Key Initiator of the PERK-CHOP Pathway of the Unfolded Protein Response.”
“The unfolded protein response in the cell plays important roles in aging and many diseases, such as cancer, diabetes, and neurodegenerative disease,” explained senior study investigator Zihai Li, M.D., Ph.D., chair of the department of microbiology and immunology at the MUSC Hollings Cancer Center. “Our study has uncovered a novel mechanism that triggers this response.”
Related Articles:
Two Breast Cancer Endocrine Therapy Drugs have Passed the Consistency Evaluation
Pregnancy Obesity Alters Fetal Liver Epigenetics and Metabolic Pathways
Increasing Sirt4 Activity May Help Treat Age-Related Metabolic Decline and Disorders
There are links between protein-folding problems at the cellular level and a range of metabolic disorders, though it is unclear if those problems are causes or manifestations of such disorders. This study provides evidence that problems with protein folding contribute to certain metabolic disorders. When improperly folded molecules are encountered in cells, the unfolded protein response (UPR) is activated within the endoplasmic reticulum (ER). The ER is in charge of molecular quality control, making sure proteins, lipids, and other molecules are folded properly before the cell attempts to use them for metabolic processes.
In the current study, the researchers found that the master protein called grp78 is in contact with three main signaling hubs that make up the control center of the UPR. When an unfolded, or misfolded protein is encountered by grp78, it breaks contact with those sensors and activates the UPR. The UPR then refolds or disposes of such molecules before they are shipped to the parts of the cell that need them.
“…we report that ER luminal protein canopy homolog 2 (CNPY2) is released from grp78 upon ER stress. Free CNPY2 then engages protein kinase R-like ER kinase (PERK) to induce expression of the transcription factor C/EBP homologous protein (CHOP), thereby initiating the UPR,” the authors wrote. “Indeed, deletion of CNPY2 blocked the PERK–CHOP pathway and protected mice from UPR-induced liver damage and steatosis. Additionally, CNPY2 is transcriptionally upregulated by CHOP in a forward-feed loop to further enhance UPR signaling. These findings demonstrate the critical roles of CNPY2 in ER stress and suggest that CNPY2 is a potential new therapeutic target for UPR-related diseases such as metabolic disorders, inflammation and cancer.”
When too many unfolded proteins build up, the UPR senses that the cell has become overstressed and activates programs to recycle the cell. Yet if some cells experience such stress and are similarly retired, whole organs can suffer. This appears to be where the CNPY2 molecule exerts influence during the development of metabolic problems.
CNPY2 has been known for some time to reside within the ER, but its function there has remained a mystery. To start, mice without CNPY2 were generated to see how they would grow. Although the rodents were slightly smaller, they were otherwise normal. Significant differences appeared, however, when they were fed tiny amounts of tunicamycin, a known inducer of the UPR. Control mice exhibited signs of liver stress and activation of PERK, one of the three main UPR sensors, while the livers of knockout mice remained stress-free. This was the first sign that CNPY2 could be involved in metabolic stress in the liver.
To test this idea more directly, the researchers fed mice a high-fat diet for several weeks. Those that lacked CNPY2 were again protected, this time from the development of hepatic steatosis, an early sign of nonalcoholic fatty liver disease (NAFLD) that develops in people who consume a diet high in fat.
Next, the researchers looked at the molecular basis of these observations. If their hypothesis was correct, they would confirm that CNPY2 was required for the development of liver problems as a result of a high-fat diet. At the molecular level, this would mean that CNPY2 interacts directly with one of the UPR sensors, which the researchers suggested would be PERK.
The investigators examined mouse cells with and without CNPY2 and isolated the PERK protein and its downstream signaling molecule, CHOP, within them. This interestingly named PERK-CHOP pathway, which is a major enabler of liver stress when the UPR is induced, was not activated in cells without CNPY2. When they added CNPY2 back to those cells, suddenly the pathway was restored. Protein isolation experiments confirmed their hypothesis that CNPY2 and PERK interacted closely when the UPR was again induced by the drug tunicamycin.
Additionally, the master protein grp78 that regulates all three main UPR sensors interacted with CNPY2 under normal conditions. But when the UPR drug was added, grp78 left CNPY2 able to interact closely with PERK, which finally activated the PERK-CHOP pathway. Last, they found that the PERK-CHOP pathway, when activated by free CNPY2, further increased levels of CNPY2 in the liver. In other words, CNPY2 was able to reinforce itself further once activated.
Taken together, the team’s experiments showed that CNPY2 powerfully sustains cellular stress when the unfolded protein response becomes active, providing a link between the UPR and the development of metabolic problems in the liver.
“This novel finding has raised the possibility of developing new treatments for metabolic diseases by targeting CNPY2,” Dr. Hong concluded.
评论
发表评论